Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Chamie, Karim; Chang, Sam S.; Kramolowsky, Eugene V.; Gonzalgo, Mark L.; Huang, Megan; Bhar, Paul; Spilman, Patricia; Sender, Lennie; Reddy, Sandeep K.; Soon-Shiong, Patrick

doi:10.1097/upj.0000000000000517

Urology Practice

2024

DOI: 10.1097/upj.0000000000000517

|View full text |Cite

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Karim Chamie,

Sam S. Chang,

Eugene V. Kramolowsky

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment

Montgomery,

Lybbert,

Sana

et al. 2024

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment

Montgomery,

Lybbert,

Sana

et al. 2024

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer

Gupta,

Verma,

Gupta

2024

ann urol oncol

View full text Add to dashboard Cite

Bacillus Calmette-Guérin (BCG) is the standard treatment for patients with non-muscle invasive bladder cancer (NMIBC). Although this therapy has been effective, BCG resistance poses a significant challenge, highlighting the need for alternative treatment options. Possible alternative treatments include intravesical chemotherapy, immunotherapy, antibody-drug conjugates, device-assisted therapies, gene therapy, and radiotherapy. Although radical cystectomy is recommended after BCG failure, its high morbidity and considerable impact on patients' lives underscore the necessity of developing new treatment strategies. This review provides an outline of the current knowledge and ongoing research on alternative treatments for BCG-unresponsive high-risk NMIBC, aiming to improve patient outcomes. Considering the current global shortage of BCG, it is essential to prioritize alternative therapies as treatment options for patients with BCG-unresponsive NMIBC.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer

Cited by 2 publications

References 24 publications

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment

Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer

Contact Info

Product

Resources

About